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Activated mast cells are a major source of the eicosanoids PGD2 and leukotriene C4 (LTC4), which contribute to allergic responses.
These eicosanoids are produced following the ERK1/2-dependent activation of cytosolic phospholipase A2, thus liberating ara-
chidonic acid, which is subsequently metabolized by the actions of 5-lipoxygenase and cyclooxygenase to form LTC4 and PGD2,
respectively. These pathways also generate reactive oxygen species (ROS), which have been proposed to contribute to FcRI-
mediated signaling in mast cells. In this study, we demonstrate that, in addition to ERK1/2-dependent pathways, ERK1/2-inde-
pendent pathways also regulate FcRI-mediated eicosanoid and ROS production in mast cells. A role for the Tec kinase Btk in
the ERK1/2-independent regulatory pathway was revealed by the signiﬁcantly attenuated FcRI-dependent PGD2, LTC4, and
ROS production in bone marrow-derived mast cells of Btk
/ mice. The FcRI-dependent activation of Btk and eicosanoid and
ROS generation in bone marrow-derived mast cells and human mast cells were similarly blocked by the PI3K inhibitors, Wort-
mannin and LY294002, indicating that Btk-regulated eicosanoid and ROS production occurs downstream of PI3K. In contrast to
ERK1/2, the PI3K/Btk pathway does not regulate cytosolic phospholipase A2 phosphorylation but rather appears to regulate the
generation of ROS, LTC4, and PGD2 by contributing to the necessary Ca
2 signal for the production of these molecules. These
data demonstrate that strategies to decrease mast cell production of ROS and eicosanoids would have to target both ERK1/2- and
PI3K/Btk-dependent pathways. The Journal of Immunology, 2008, 181: 7706–7712.
M
ast cell-derived mediators play a central role in the
initiation of the inﬂammatory reactions associated
with atopic asthma and other allergic disorders (1, 2).
These mediators, which are released following Ag-dependent ag-
gregation of IgE-occupied high afﬁnity IgE receptors (FcRI) on
the mast cell surface (1, 3, 4), are broadly grouped into three main
categories: granule-associated mediators, chemokines and cyto-
kines, and eicosanoids. Much is known regarding the signaling
events leading to the release of granule-associated mediators and,
to a certain extent, cytokine production (reviewed in Refs. 3, 5).
However, the signaling events mediating eicosanoid generation are
less well deﬁned.
The eicosanoids generated in activated mast cells are primarily rep-
resented by leukotriene C4 (LTC4)
3 and PGD2 (1, 3, 6–8). Multiple
processes are required for the generation of these mediators; however,
the major initiating step is the liberation of arachidonic acid from
membrane lipids, primarily, 1-acyl, 2-arachidoyl-phosphatidylcho-
line, following hydrolysis catalyzed by cytosolic phospholipase A2
(cPLA2) (9, 10). The liberated arachidonic acid is subsequently me-
tabolized to form LTC4 and PGD2 by the actions of 5-lipoxygenase
(5-LO) and LTC4 synthase (11, 12), and cyclooxgenase (COX), re-
spectively (8, 13). Reactive oxygen species (ROS) including hy-
droperoxides, hydrogen peroxide, and superoxide are formed during
the generation of both LTC4 and PGD2 (14, 15). ROS have been
proposed to regulate mast cell responses; however, these conclusions
remain controversial. In this respect, although it has been suggested
that ROS are involved in the signals leading to degranulation and
cytokine secretion in mast cells (16, 17), other studies have concluded
that FcRI-dependent degranulation and cytokine production is inde-
pendent of ROS production (14).
The ability of cPLA2 to generate free arachidonic acid requires
cPLA2 to be phosphorylated, thus activated, and for it to be trans-
located to the membrane, allowing access to its phospholipid sub-
strate(s) (9, 11, 18). The phosphorylation of cPLA2 appears to be
mediated by the MAPK ERK1/2, whereas its translocation is de-
pendent on Ca
2 (19–22). ROS production is also a Ca
2-depen-
dent process (17), but the upstream events required for ROS pro-
duction and cPLA2 activation have not been fully delineated.
In human mast cells (HuMCs), we have previously demon-
strated that both PI3K-dependent and -independent pathways con-
tribute to the increase in cytosolic Ca
2 concentrations required
for mast cell degranulation (23). The PI3K-dependent pathway ap-
pears to be mediated through the Tec kinase Btk. We (24) and
others (25, 26) have shown that Btk enhances FcRI-mediated
PLC1 activation in a PI3K-dependent manner. Therefore, it is
possible that Btk may similarly contribute to the regulation of the
Ca
2 signal required for eicosanoid generation and ROS produc-
tion in activated mast cells. In this study, we show that both ERK1/
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LTC4 and PGD2 generation and ROS production. The generation
of these products was substantially reduced in parallel with the
Ca
2 signal in Btk-deﬁcient mast cells and in wild-type (WT) mast
cells treated with PI3K inhibitors, providing the ﬁrst evidence that
activation of a PI3K-Btk-PLC pathway is required for the Ca
2-
dependent production of eicosanoids and ROS in FcRI-mediated
activated cells. The recognition of the complementary signaling
pathways required for FcRI-mediated eicosanoid and ROS gen-
eration implies that therapeutic approaches to block the generation
of these products require a coordinated strategy targeting these
pathways.
Materials and Methods
Cell isolation and mast cell culture
The Btk knockout, kindly provided by Dr. Anne B. Satterthwaite (Univer-
sity of Texas Southwestern Medical Center, Dallas, TX), and the WT mice
used in this study have been described (24). Mice were backcrossed with
C57BL/6J (The Jackson Laboratory) over six generations. The WT mice
were derived from the same parental lines as the knockout mice. The ge-
notype of these mice was conﬁrmed by RT-PCR of tail biopsies (data not
shown). Mouse bone marrow-derived mast cells (BMMCs) were obtained
by ﬂushing bone marrow progenitors from the femurs of the mice then
culturing the cells for 4–6 wk in RPMI 1640 medium containing IL-3 (30
ng/ml) (Peprotech) as described (23, 27).
Primary HuMCs were obtained from CD34
 peripheral blood progen-
itor cells grown in StemPro-34 culture media containing recombinant hu-
man IL-3 (30 ng/ml) (ﬁrst week only), IL-6 (100 ng/ml), and stem cell
factor (100 ng/ml) (Peprotech) as described (23, 28). Experiments were
conducted on these cells 7–10 wk after the initiation of culture, at which
point, the population was greater than 99% mast cells as assessed by to-
luidine blue staining.
Cell activation
HuMCs or BMMCs were sensitized overnight with an optimal concentra-
tion (100 ng/ml) of biotinylated human IgE or mouse SPE-7 (IgE anti-
DNP) (Sigma-Aldrich), respectively, in cytokine-free medium. The fol-
lowing day, the cells were washed with HEPES buffer (10 mM HEPES [pH
7.4], 137 mM NaCl, 2.7 mM KCl, 0.4 mM Na2HPO47H2O, 5.6 mM glu-
cose, 1.8 mM CaCl22H2O, and 1.3 mM MgSO47H2O) containing 0.04%
BSA (Sigma-Aldrich) to remove excess IgE then the cells resuspended in
this buffer at the required cell density for a speciﬁc assay. The BMMCs or
HuMCs were stimulated with DNP-HSA (10 ng/ml) or with streptavidin
(SA; 10 ng/ml), both also referred to as Ag, at 37°C, respectively.
Intracellular ROS detection by microﬂuorometry
Intracellular ROS were measured as described (14). Brieﬂy, sensitized
mast cells were preincubated with or without indicated inhibitors at 4°C for
10–20 min. After centrifugation, cells were incubated with dichloroﬂuo-
rescein (DCF)-diacetate (20 M) (EMD Biosciences) in cell culture me-
dium for 20 min at 4°C. Cells were then washed with HEPES buffer con-
taining 0.04% BSA and seeded at 2  10
5 cells per well in a black opaque
96-well microplate in the presence or absence of inhibitors and/or Ag. DCF
ﬂuorescence was monitored at 37°C in 1 min intervals for 20–30 min using
a GENios ﬂuorescent plate reader (ReTiSoft) with an excitation wave-
length of 492 nm and emission wavelength of 535 nm. Fluorescence was
expressed as relative ﬂuorescent units.
LTC4 and PGD2 measurements
The release of LTC4 and PGD2 from Ag-triggered cells was measured as
described (14). Brieﬂy, IgE-sensitized HuMCs or BMMCs were preincu-
bated with or without indicated inhibitors for 20 min before add DNP-HSA
(10 ng/ml, BMMCs) or SA (10 ng/ml, HuMCs) for 20 min, and then
cell-free supernatants were analyzed for LTC4 and PGD2 by competitive
enzyme immunoassay (Cayman Chemicals) according to the manufactur-
er’s instructions. For comparison, the results are proportionally represented
to ng/ml in 100,000 cells/100 l.
Immunoblotting
For immunoblot analyses, mast cell lysates were prepared as described (27,
29) and proteins separated by electrophoresis on 4–12% NuPAGE BisTris
gels (Invitrogen). Following membrane transfer, proteins were probed us-
ing the following Abs: anti--actin mAb (clone AC-15) (Sigma-Aldrich);
anti-phospho-PLC2 (Tyr(P)-759) pAb, anti-phospho-AKT (Ser(P)-473)
pAb, anti-phospho-ERK1/2 (Thr(P)-202, Tyr(P)-204) pAb, anti-phospho-
cPLA2 (Ser(P)-505) pAb, anti-cPLA2 pAB, anti-ERK pAb, anti-AKT (Cell
Signaling); anti-phospho-PLC1 (Tyr(P)-783) pAb (BIOSOURCE; Invitro-
gen), anti-phospho-Btk (Tyr(P)-551) mAb (BD Biosciences), anti-PLC1
FIGURE 1. The generation of eicoanoids and ROS
(A and B) and phosphorylation of cPLA2 and ERK1/2
(C and D) in Ag-challenged human (A and C) and
mouse (B and D) mast cells. IgE-sensitized HuMCs and
BMMCs were stimulated with SA (10 ng/ml) or DNP-
HSA (10 ng/ml), respectively, for the indicated times,
then cell-free supernatants were analyzed for LTC4 and
PGD2 content (A and B). ROS generation was moni-
tored by DCF ﬂuorescence at 37°C for up to 30 min at
1-min intervals (A and B). cPLA2 and ERK1/2 phos-
phorylation was determined by immunoblot analysis as
discussed in Materials and Methods. Experiments not
shown revealed that the apparent delay in the ROS pro-
duction shown in this and subsequent ﬁgures was a
technical artifact reﬂecting the time required for the
cells to reach optimal temperature (37°C) (C and D).
Protein levels were normalized to cPLA2 or ERK then
to Ag responses at 10 min to determine the relative in-
tensities presented under each blot. A and B, Results are
means  SE of three separate experiments performed in
duplicate for LTC4 and PGD2 generation and kinetic
graphs representative of three separate experiments for
ROS production. C and D, The blots are representative
of three independent experiments.
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tein loading, membranes were stripped and probed for -actin, or alterna-
tively identically loaded samples were probed for -actin. Changes in pro-
tein phosphorylation were determined by scanning the ECL ﬁlms using a
Quantity One scanner (Bio-Rad).
Intracellular Ca
2 determination
Sensitized BMMCs were incubated with Fura 2-AM (2 M) (Molecular
Probes) for 30 min at 37°C, washed, and resuspended in HEPES buffer
containing 0.04% BSA and sulﬁnpyrazone (0.3 mM) (Sigma-Aldrich), and
then Ca
2 ﬂux was measured as described (23). Fluorescence was mea-
sured at two excitation wavelengths (340 and 380 nm) and an emission
wavelength of 510 nm. The ratio of the ﬂuorescence readings was calcu-
lated following subtraction of the ﬂuorescence of the cells that had not been
loaded with Fura 2-AM.
IP3 assay
Sensitized WT or Btk
/ BMMCs (2  10
6) were stimulated with DNP-
HSA (10 ng/ml) for 30 s and then cellular IP3 concentrations were deter-
mined as described (27) using a commercially available kit (GE Health-
care) according to the manufacturer’s instructions. The results are
expressed as picomoles of IP3 per 2  10
6 cells.
Statistical analysis
Data are represented as the mean  SE. The statistical analyses were per-
formed by unpaired Student’s t test. Differences were considered signiﬁ-
cant when p  0.05. The n values represent experiments from multiple
preparations.
Results
ERK1/2-dependent cPLA2 activation and eicosanoid and ROS
generation in primary cultured human and mouse mast cells
Since it has been demonstrated that FcRI-mediated cPLA2 acti-
vation is dependent on phosphorylation of cPLA2 by ERK in the
RBL 2H3 rat mast cell line (20), we examined whether cPLA2-
mediated eicosanoid and ROS generation were similarly regulated
in an ERK1/2-dependent manner in primary cultured human and
mouse mast cells. SA- or DNP-HSA-induced FcRI aggregation,
as shown in Fig. 1, A and B, respectively, resulted in a rapid in-
crease in PGD2 and LTC4 release and ROS production in both
HuMCs and mouse BMMCs. As discussed in the ﬁgure legend, the
apparent delay in ROS production represented a technical artifact
due to the time required for the cells to reach 37°C. In HuMCs,
PGD2 was the predominant eicosanoid produced, whereas, in the
FIGURE 2. The effect of the ERK1/2 inhibitor on ERK1/2 and cPLA2
phosphorylation (A and B) and eicosanoid (C–F) and ROS generation (G
and H) in Ag-challenged human (A, C, E, and G) and mouse (B, D, F, and
H) mast cells. HuMCs and BMMCs were pretreated with or without U0126
for 15–20 min before stimulation with SA (10 ng/ml) or DNP-HSA (10
ng/ml), respectively, for the indicated times. cPLA2 and ERK1/2 phos-
phorylation (A and B) was determined by immunoblot analysis as described
for Fig. 1. Protein levels were normalized to cPLA2 or ERK then to the Ag
response in the absence of inhibitor to determine the relative intensities
presented under each blot. For eicosanoid release, HuMCs (C and E)o r
BMMCs (D and F) were preincubated with or without U0126 for 15–20
min before stimulation with Ag for 20 min and cell-free supernatants were
analyzed for LTC4 and PGD2. ROS generation (G and H) was monitored,
as described for Fig. 1, at 37°C at indicated times. The blots (A and B) are
representative of three independent experiments. When compared at the 10
M concentration, U0126 signiﬁcantly inhibited ERK phosphorylation and
cPLA2 phosphorylation in both HuMCs and BMMCs (p  0.05). Results
are for LTC4 and PGD2 release (C–F) are means  SE of three separate
experiments, and ROS data (G and H) are representative of three separate
experiments. , p  0.05 for comparison with Ag alone by Student’s t test.
FIGURE 3. The effects of the PI3K inhibitor Wortmannin (A and B) and
the PLC inhibitor U73122 (C and D) on cPLA2 and ERK1/2 phosphory-
lation in human (A and C) and mouse (B and D) mast cells. IgE-sensitized
HuMCs or BMMCs were pretreated with or without indicated inhibitors
(Wortmannin 100 nM, U73122 1 M) for 15 min before stimulation with
SA (10 ng/ml) or DNP-HSA (10 ng/ml), respectively, for the indicated
times. cPLA2 and ERK1/2 phosphorylation was determined by immuno-
blot analysis as described for Fig. 1. Protein levels were normalized to
cPLA2 or ERK then to the Ag response responses at 10 min to determine
the relative intensities presented under each blot. The blots are represen-
tative of three independent experiments.
7708 EICOSANOID AND ROS GENERATION IN MAST CELLSmouse BMMCs, LTC4 was the predominant form. Except for
PGD2 release in BMMCs, maximal release in each case was ob-
served within 10 min of cell activation. These observations are
consistent with the kinetics observed in RBL 2H3 cells (20). Over
this time frame, the phosphorylation of ERK1/2 and cPLA2 was
similarly observed to increase following FcRI aggregation in
HuMCs (Fig. 1C) and mouse BMMCs (Fig. 1D). Maximum
ERK1/2 phosphorylation appeared to slightly precede the maxi-
mum increase in cPLA2 phosphorylation.
To determine whether ERK1/2 participated in cPLA2 activation
and eicosanoid and ROS generation in primary cultures of mouse
and human mast cells, we next examined the ability of the MEK1/2
inhibitor U0126 to block these responses. As expected, U0126
markedly inhibited FcRI-dependent ERK1/2 phosphorylation in
both HuMCs (Fig. 2A) and BMMCs (Fig. 2B) in a concentration-
dependent manner between 1 and 10 M, while having minimal
effect on the phosphorylation of the MAPKs p38 and JNK over this
concentration range (data not shown). Similarly, U0126 (10 M)
signiﬁcantly inhibited FcRI-mediated cPLA2 phosphorylation
(HuMCs: Fig. 2A; BMMCs: Fig. 2B), LTC4 (HuMCs: Fig. 2C;
BMMCs: Fig. 2D), and PGD2 (HuMCs: Fig. 2E; BMMCs: Fig.
2F) generation. ROS production was also markedly inhibited by
U0126 (HuMCs: Fig. 2G, BMMCs: Fig. 2H), suggesting that ROS
production in these cells was also regulated by ERK. HuMCs ap-
peared to be more sensitive to the effects of U0126 on ROS pro-
duction compared with BMMCs. Thus, both the production of ei-
cosanoids and ROS in primary cultures of mouse and human mast
cells is, in part, regulated by an ERK1/2-dependent pathway.
The degree of inhibition of eicosanoid production (LTC4 87%,
PGD2 90% inhibition in HuMCs; LTC4 68%, PGD2 57% inhibi-
tion in BMMCs, both at 10 M of U0126), however, was greater
than that observed for cPLA2 phosphorylation (52% in both
HuMCs and BMMCs at 10 M of U0126). In addition, the titra-
tion curves for the effects of U0126 on LTC4 and PGD2 production
in either HuMCs or BMMCs (Fig. 2, C–F) only partially correlated
with that for cPLA2 phosphorylation. These data led us to inves-
tigate whether other pathways contribute to the regulation of
cPLA2 activation leading to eicosanoid generation in activated
mast cells.
PI3K- and PLC-regulated FcRI-mediated eicosanoid and
ROS generation
PI3K and PLC1 regulate two key intermediary signaling path-
ways for Ag-mediated mast cell degranulation (23). The effects
of respective inhibitors of these enzymes, Wortmannin and
U73122, on cPLA2 activation and eicosanoid and ROS gener-
ation were thus examined. As shown in Fig. 3, both compounds
FIGURE 4. The effect of PI3K and PLC inhibitors on eicosanoid (A and
C) and ROS generation (B and D) in human (A and B) and mouse (C and
D) mast cells. IgE-sensitized HuMCs and BMMCs were pretreated with or
without indicated inhibitors (Wortmannin 100 nM, LY294002 10 M,
U73122 1 M) for 15 min. Following treatment with SA (10 ng/ml) or Ag
(10 ng/ml), cell-free supernatants were analyzed for LTC4 and PGD2 con-
tent and cellular ROS generation was monitored as described in Materials
and Methods at indicated time points. Results are means  SE of three
separate experiments performed in duplicate for LTC4 and PGD2 genera-
tion and representative of three separate experiments for ROS production.
, p  0.05 for comparison with Ag alone by Student’s t test.
FIGURE 5. Eicosanoid release (A and B) and ROS generation (C)i n
Btk
/ and WT BMMCs. WT and Btk
/ BMMCs were sensitized and
treated with Ag (10 ng/ml) for 20 min and cell-free supernatants were
analyzed for LTC4 and PGD2 release and ROS generation as described for
Fig. 1. The results are means  SE of three separate experiments per-
formed in duplicate for LTC4 and PGD2 generation and representative of
three separate experiments for ROS production. , p  0.05 for comparison
with Ag alone by Student’s t test.
7709 The Journal of Immunologyinhibited (25–40%) FcRI-mediated of ERK1/2 phosphoryla-
tion 10 min after stimulation of both HuMCs (Fig. 3, A and C) and
BMMCs (Fig. 3, B and D). However, neither Wortmannin nor
U73122 signiﬁcantly inhibited cPLA2 phosphorylation. These data
show that although ERK is partially regulated by PI3K, FcRI-
mediated cPLA2 phosphorylation is independent of PI3K activa-
tion. However, these inhibitors as well as LY294002, another PI3K
inhibitor, signiﬁcantly reduced FcRI-mediated LTC4 and PGD2
release and ROS production (HuMCs: Fig. 4, A and B, BMMCs:
Fig. 4, C and D). However, at 100 nM and 10 M, respectively,
Wortmannin and LY294002 only partially inhibited these re-
sponses. As previously shown (27), and as discussed later, these
concentrations completely block PI3K-dependent Akt phosphory-
lation in mast cells. This is consistent with the conclusion that,
although PLC is absolutely required for FcRI-dependent eico-
sanoid generation, a PI3K-independent pathway is involved in ad-
dition to a PI3K-dependent pathway.
The role of Btk in PI3K- and PLC-dependent eicosanoid and
ROS generation
Because Btk is a possible intermediary in the PI3K-dependent reg-
ulation of PLC1, (30) we next examined whether Btk played a
similar role in the regulation of eicosanoid generation following
FcRI aggregation. For these studies, we used BMMCs derived
from the bone marrow of Btk
/ and Btk
/ (WT) mice. Fig. 5
shows that there was a partial attenuation of FcRI-mediated
PGD2, LTC4, and ROS generation in the Btk
/ BMMCs. The
degree of inhibition mimicked the partial inhibition of PGD2 and
LTC4 production observed in the cells treated with PI3K inhibitors
but was less than that achieved in cells treated with the PLC
inhibitor U73122.
In the Btk
/ BMMCs, there was a signiﬁcant inhibition of PLC1
and PLC2 but not AKT phosphorylation (Fig. 6A). Similarly
FIGURE 6. PLC activation (A and B), calcium mobilization (C), and
cPLA2 phosphorylation (D)i nB t k
/ and WT BMMCs. A and D, IgE-
sensitized WT BMMCs and Btk
/ BMMCs were treated with Ag (10
ng/ml) for the indicated times. Btk, PLC, and AKT phosphorylation was
determined by immunoblot analysis as described for Fig. 1. Protein levels
were normalized to the nonphosphorylated proteins then to Ag responses at
10 min to determine the relative intensities presented under each blot. B,
Sensitized BMMCs from WT or Btk
/ were stimulated with DNP-HSA
(10 ng/ml) for 30 s then IP3 levels determined as described in Materials
and Methods. C, BMMCs from WT or Btk
/ BMMCs were loaded with
Fura 2-AM then changes in intracellular Ca
2 concentrations in response
to DNP-HSA 10 ng/ml were determined at the indicated time points. The
protein blots (A and D) are representative of three independent experi-
ments. When compared with the WT controls at 10 min, PLC1 and PLC2
phosphorylation were signiﬁcantly lower in the Btk
/ BMMCs (p 
0.05). The data (B)( n  4) are presented as means  SE of separate
experiments conducted in duplicate. The Ca
2 data are representative of
n  3 experiments conducted in duplicate. For calcium results, when com-
pared at the 300 s point, and for indicted values in other graphs, , p  0.05
for comparison with Ag response in WT by Student’s t test.
FIGURE 7. The effect of PI3K inhibitors on PLC and BTK phosphor-
ylation (A), and the effect of inhibitors of the calcium signal on eicosanoid
release (B and C) and ROS generation (D) in BMMCs. A, IgE-sensitized
BMMCs were pretreated with or without indicated inhibitors (Wortmannin
100 nM, LY294002 10 M) for 15 min followed by treatment with Ag (10
ng/ml) for the indicated times. Protein levels were normalized to nonphos-
phorylated proteins then to Ag responses at 10 min to determine the rela-
tive intensities presented under each blot. B and C, BMMCs were pre-
treated with or without indicated inhibitors (2-APB 50 M, EDTA 5 mM)
for 15 min. Following treatment with DNP-HSA (10 ng/ml), cell-free su-
pernatants were analyzed for LTC4 and PGD2. D, ROS generation was
monitored as described for Fig. 1. The blots (A) are representative of three
independent experiments. Wortmannin and LY294002 signiﬁcantly inhib-
ited AKT, PLC1 and 2, and Btk phosphorylation (p  0.05). Results (B
and C) are means  SE of three separate experiments performed in du-
plicate for LTC4 and PGD2 generation, and the ROS generation (D)i s
representative of three separate experiments. , p  0.05 for comparison
with Ag alone by Student’s t test.
7710 EICOSANOID AND ROS GENERATION IN MAST CELLSPLC-dependent IP3 production (Fig. 6B) and in agreement with
previous observations (24, 26), Ca
2 mobilization (Fig. 6C) was
also attenuated in the Btk
/ BMMCs. The defect in Ca
2 mo-
bilization in the Btk
/ BMMCs mirrored a similar decrease ob-
served in WT BMMCs treated with the PI3K inhibitors Wortman-
nin and LY 294002 (data not shown). No defects were observed in
FcRI-mediated ERK1/2 and cPLA2 phosphorylation in the
Btk
/ BMMCs (Fig. 6D).
The above data suggested that Btk regulated cPLA2 activation
as well as eicosanoid and ROS generation upstream of the PLC-
mediated Ca
2 signal. The unimpaired AKT phosphorylation in
Btk
/ BMMCs indicated that Btk was downstream of PI3K. This
conclusion is supported by the fact that phosphorylation of Btk,
PLC1, and PLC2 was reduced following treatment of WT
BMMCs with the PI3K inhibitors (Fig. 7A).
To determine whether the observed defect in Ca
2 mobilization
observed in the Btk
/ BMMCs and WT BMMCs treated with the
PI3K or PLC inhibitor accounts for the inhibition of eicosanoid
and ROS generation, we used the Ca
2 chelator EDTA and the IP3
receptor antagonist 2-APB. Both ablated the FcRI-mediated Ca
2
signal in BMMCs (data not shown). These agents also blocked
FcRI-mediated PGD2, LTC4, and ROS production to a similar
extent to that observed following treatment of the cells with the
PLC inhibitor U73122 (Fig. 4). These data demonstrated that all
three responses were dependent on Ca
2. Therefore, it is reason-
able to conclude that Btk regulates eicosanoid and ROS generation
in part through its regulation of the Ca
2 signal.
Discussion
In this study, and as summarized in Fig. 8, we have demonstrated
that PI3K and Btk are required for optimal FcRI-mediated cPLA2
activation leading to COX- and 5-LO-mediated generation of ei-
cosanoids and ROS (Fig. 1) in mast cells. The PI3K-Btk axis ap-
pears to regulate these responses by the latent regulation of the
PLC-induced calcium signal, which is essential for cPLA2 acti-
vation and which likely also contributes to the regulation of COX
and 5-LO. Rather than leading to cPLA2 phosphorylation, which is
regulated to a certain extent by an ERK1/2-dependent mechanism,
the calcium-dependent regulation of eicosanoid and ROS genera-
tion by PI3K and Btk may lead to the binding of Ca
2 to the C2
domain of cPLA2, which regulates membrane targeting.
The role of ERK1/2 in cPLA2 phosphorylation leading to eico-
sanoid generation previously reported in RBL 2H3 cells (20) was
conﬁrmed in human and mouse mast cells by the concurrent Ag-
dependent increase in ERK1/2 and cPLA2 phosphorylation in
HuMCs and BMMCs (Fig. 1) and, more speciﬁcally, by the ability
of the MEK1/2 inhibitor U0126 to attenuate these responses in
parallel with the attenuation of PGD2 and LTC4 release (Fig. 2,
A–F). These studies also revealed a role of ERK1/2 in the produc-
tion of ROS (Fig. 2, G and H). Nevertheless, the effects of U0126
on the aforementioned responses were partial, suggesting that
other pathways are involved in these responses.
The role of PI3K and Btk in the ERK-independent regulation of
eicosanoid and ROS generation was indicated by the ability of
PI3K inhibitors to reverse FcRI-mediated PGD2 and LTC4 re-
lease and ROS production in both HuMCs and BMMCs (Fig. 4),
and by the substantial reduction of these responses in Btk
/
BMMCs. (Fig. 5). These data obtained from the Btk
/ BMMCs,
however, are in contrast to a previous report of unimpaired FcRI-
mediated LT release in these cells (26). The reason for the dispar-
ity is currently unclear. However, the ability of the PI3K inhibitors
to block Btk activation (Fig. 7A) and mimic the Btk
/ phenotype
(Figs. 4 and 5) indicates that PI3K contributes to the control of
eicosanoid and ROS generation by regulating the activity of Btk.
It is possible, however, that PI3K also acts independently of Btk.
For example, it has been reported that PI3K/Rac/PKC acts up-
stream of ERK and cPLA2 to regulate FcRI-mediated cysteinyl
leukotriene synthesis in RBL 2H3 cells (31). Regardless, the small
differences noted in phosphorylation of cPLA2 (Figs. 3, A and B,
and 6D) implies that PI3K and Btk were regulating eicosanoid and
ROS generation other than through control of ERK1/2-mediated
cPLA2 phosphorylation. This conclusion was further supported by
the lack of difference in the phosphorylation of ERK1/2 in the
Btk
/ BMMCs (Fig. 6D).
Although the PI3K inhibitors produced a slight reduction in
FcRI-mediated ERK1/2 phosphorylation (Fig. 3, A and B), this
did not translate to reduced cPLA2 phosphorylation. It may be
argued that the degree of inhibition of ERK1/2 phosphorylation
produced by the PI3K inhibitors (42% in HuMCs, 39% in BMMCs
at 10 min of stimulation) was not of sufﬁcient magnitude to reduce
the phosphorylation of cPLA2. However, it is also possible that the
inhibitors of the ERK1/2 pathway used in this and a previous study
(19) may be also targeting other kinase pathways leading to cPLA2
phosphorylation.
The ability of the Ca
2-chelator EDTA and the IP3 receptor
antagonist 2-APB to block Ag-induced eicosanoid generation and
ROS production (Fig. 7, B–D) demonstrates the requirement for an
increase in cytosolic Ca
2 concentrations for the liberation of free
arachidonic acid, and the subsequent production of PGD2 and
FIGURE 8. Proposed mechanism of FcRI-induced eicosanoid and
ROS generation. FcRI aggregation induces Btk activation, which is down-
stream of PI3K. Activated Btk contributes to the PLC-induced Ca
2 sig-
nal, which is essential for cPLA2, COX, and 5-LO activation. Whereas
activated ERK1/2 leads to cPLA2 activation through its phosphorylation,
the Ca
2 provided by the PI3K-Btk likely activates cPLA2 by binding to
the C2 domain. The sites of action of the inhibitors and gene knock out
used in this study are indicated in the ﬁgure.
7711 The Journal of ImmunologyLTC4, as well as ROS, in activated mast cells. In addition to phos-
phorylation, cPLA2 activation requires translocation from the cy-
tosol to the perinuclear membrane. This translocation is induced in
response to an increase in intracellular Ca
2, and subsequent bind-
ing of Ca
2 to the C2 domain of cPLA2 resulting in increased
afﬁnity of cPLA2 for membranes (21, 22). Both COX and 5-LO
also require Ca
2 for activity (Fig. 7, B and C) and translocation
to the perinuclear membrane. Thus, the results of the experiments
conducted with EDTA and 2-APB can be explained by an inhibi-
tion of cPLA2 activation through reducing the effective concentra-
tions of Ca
2, which interact with the C2 domain of cPLA2.
In this (Fig. 6C) and in previous studies (24), we have demon-
strated that PI3K and Btk contribute to the Ca
2 signal induced
upon FcRI aggregation in mast cells. Therefore, it is likely that
PI3K and Btk regulate eicosanoid and ROS generation by this
means. This pathway likely involves a latent signal that allows the
maintenance of PLC activation, which is induced upon FcRI
aggregation. In agreement with previous reports (24, 26), we ac-
cordingly observed that FcRI-mediated PLC phosphorylation
and PLC-dependent IP3 production were partially attenuated in
Btk
/ cells (Fig. 6) and in BMMCs treated with the PI3K inhib-
itors (Fig. 7A). This level of inhibition was similar to the degree of
attenuation of FcRI-mediated eicosanoid and ROS generation ob-
served under similar experimental conditions. The results obtained
under Ca
2-free conditions and with the IP3 binding inhibitor
2-APB, however, demonstrate that there is an absolute requirement
for both the PLC-mediated generation of IP3 and Ca
2 for FcRI-
mediated eicosanoid and ROS generation in mast cells (Fig. 7,
B–D). The residual calcium signal and eicosanoid and ROS gen-
eration observed in Btk
/ (Fig. 6C) cells and WT BMMCs
treated with the PI3K inhibitors (data not shown), therefore, sug-
gests that other, as yet unidentiﬁed, signals may also contribute to
the aforementioned responses.
In summary, the results of this study demonstrate that ERK1/2-
and PI3K-Btk-dependent pathway (Fig. 8) independently contrib-
ute to Ag-mediated generation of eicosanoids and ROS in mast
cells. Whereas ERK1/2 regulates cPLA2 phosphorylation, the
PI3K-Btk pathway contributes to the required Ca
2 signal for
cPLA2, COX, and 5-LO activation. Therefore, effective therapeu-
tic suppression of eicosanoid and ROS production in activated
mast cells may require a combination of strategies to block both
ERK- and PI3K/Btk-regulated pathways.
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